ScripBayer’s hopes of launching elinzanetant onto the US market this summer have been dashed by the US Food and Drug Administration which needs more to time to evaluate the company’s submission for the clo
ScripThe second half of this year could bring two major new approvals for Boehringer Ingelheim, with lung cancer drug zongertinib and idiopathic pulmonary fibrosis candidate nerandomilast both currently un
Pink SheetThe US Food and Drug Administration’s approval decisions for novel agents will come from different divisions in the second half of 2025, compared to the first half, the Pink Sheet ’s US FDA Performan
ScripBayer AG has been touting Kerendia (finerenone) as a blockbuster sales product in both kidney and cardiovascular disease for several years, and a July 14 US Food and Drug Administration approval for